Product Name: Human NKG2A Antibody (Monalizumab, Research Use)
Catalog Number: NBR-0257
Target Name: NKG2A
Trade Name: Monalizumab
Antibody Drug Description: Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: NKG2A
Synonyms: CD159a; NKG2; NKG2-A; NKG2-B
Target Description: Immune inhibitory receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia molecules. 
Ensembl: ENSG00000134545 
Uniprot: P26715